Bevacizumab for the Treatment of Glioblastoma

Glioblastoma (GBM) or grade IV glioma is the most common primary brain tumor in adults. Standard treatment median overall survival (OS) is only 14–15 months and less than 10% of patients will survive 5 years after diagnosis. There is no standard treatment in recurrent GBM and OS ranges from 3 to 9 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Gil-Gil, Miguel J., Mesia, Carlos, Rey, Montserrat, Bruna, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682734/
https://www.ncbi.nlm.nih.gov/pubmed/23843722
http://dx.doi.org/10.4137/CMO.S8503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682734/
https://www.ncbi.nlm.nih.gov/pubmed/23843722
http://dx.doi.org/10.4137/CMO.S8503

Ejemplares similares